On September 30, 2026 Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, reported that three abstracts from its Radspherin program have been accepted for presentation at the European Association of Nuclear Medicine (EANM) Annual Congress 2026 in Vienna, Austria (17-21 October) and the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 in Madrid, Spain (23-27 October).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The accepted abstracts highlight key areas of the Radspherin program, including Radium-224 production technology, radiation dosimetry and the ongoing Phase 2 clinical evaluation of Radspherin in ovarian cancer. Two abstracts will be presented at EANM and one at ESMO (Free ESMO Whitepaper).
Øystein Soug, Chief Executive Officer of Oncoinvent, said: "We are pleased to have three abstracts accepted for presentation at EANM and ESMO (Free ESMO Whitepaper) 2026. Together, they highlight research across the Radspherin program, from Radium-224 production and radiation dosimetry to ongoing clinical development in ovarian cancer. We look forward to sharing our work with the scientific community at both meetings."
EANM 2026:
Abstract Title: A228Th/224Ra Generator Based on Citrate Solution for Production of High-Purity 224Ra for Radiopharmaceuticals
Session Title: The Science of Radiopharmaceutical Preparation
Date & Time: Monday, 19 October 2026, 08:48 – 08:52 CEST
Location: Hall G2
Session number: EPS-098
Session Number: 709
Abstract Title: Dosimetry of the Peritoneum from Radium-224 Calcium Carbonate Microparticles Estimated Using Monte Carlo Simulations
Format: Digital e-Poster
Session Number: EP-67
ESMO 2026:
Abstract Title: A Phase 2 Randomised Trial of Intraperitoneal α-emitting Radium 224 for Homologous Recombination Proficient Primary Advanced Epithelial Ovarian Cancer – Trial in Progress
Session Title: Gynaecological cancers
Date & Time: Saturday, 24 October 2026, 14
Location: Barcelona Auditorium – Hall 9
Presentation Number: 1446eTiP
Presentation Format: e-Poster
(Press release, Oncoinvent, SEP 30, 2026, https://www.oncoinvent.com/press-release/oncoinvent-to-present-three-abstracts-at-eanm-and-esmo-2026/ [SID1234671158])